Anika Therapeutics, Inc. (NASDAQ:ANIK) Short Interest Down 5.0% in September

Anika Therapeutics, Inc. (NASDAQ:ANIK) saw a large decrease in short interest in September. As of September 30th, there was short interest totalling 639,300 shares, a decrease of 5.0% from the September 15th total of 673,300 shares. Based on an average trading volume of 50,200 shares, the days-to-cover ratio is presently 12.7 days. Currently, 4.5% of the shares of the company are short sold.

Hedge Funds Weigh In On Anika Therapeutics

Several hedge funds have recently modified their holdings of the stock. SG Americas Securities LLC increased its holdings in Anika Therapeutics by 43.1% in the 3rd quarter. SG Americas Securities LLC now owns 9,485 shares of the biotechnology company’s stock valued at $234,000 after acquiring an additional 2,858 shares during the last quarter. Stonepine Capital Management LLC grew its position in shares of Anika Therapeutics by 171.4% during the second quarter. Stonepine Capital Management LLC now owns 165,397 shares of the biotechnology company’s stock valued at $4,190,000 after purchasing an additional 104,448 shares in the last quarter. Ironwood Investment Management LLC increased its holdings in shares of Anika Therapeutics by 109.9% in the second quarter. Ironwood Investment Management LLC now owns 28,704 shares of the biotechnology company’s stock worth $727,000 after purchasing an additional 15,032 shares during the last quarter. Meros Investment Management LP lifted its position in shares of Anika Therapeutics by 25.0% in the second quarter. Meros Investment Management LP now owns 212,714 shares of the biotechnology company’s stock worth $5,388,000 after buying an additional 42,587 shares in the last quarter. Finally, AQR Capital Management LLC boosted its stake in Anika Therapeutics by 8.1% during the second quarter. AQR Capital Management LLC now owns 107,373 shares of the biotechnology company’s stock valued at $2,720,000 after buying an additional 8,072 shares during the last quarter. Hedge funds and other institutional investors own 91.53% of the company’s stock.

Anika Therapeutics Stock Down 0.2 %

NASDAQ:ANIK opened at $25.15 on Friday. The business’s 50-day simple moving average is $25.13 and its two-hundred day simple moving average is $25.83. Anika Therapeutics has a 52 week low of $18.08 and a 52 week high of $29.11. The stock has a market cap of $366.86 million, a PE ratio of -4.79 and a beta of 0.83.

Anika Therapeutics (NASDAQ:ANIK) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.24). Anika Therapeutics had a negative net margin of 44.45% and a positive return on equity of 0.94%. The business had revenue of $41.92 million for the quarter, compared to the consensus estimate of $39.90 million. During the same period last year, the business posted ($0.06) EPS. Sell-side analysts anticipate that Anika Therapeutics will post -0.1 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Barrington Research reaffirmed an “outperform” rating and set a $37.00 price target on shares of Anika Therapeutics in a report on Friday, August 9th.

About Anika Therapeutics

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.